The LAB: Value Creation in Private Equity

George provides several concrete, actionable frameworks (ICP+segmentation, repeatable sales process, pipeline verification, foundation-building metaphor) that operators would find useful, but the episode spends considerable time on foundational concepts rather than novel insights. The specificity around diagnostics and rapid response initiatives adds substance, but much of the content centers on relatively standard GTM best practices (people-process-technology, sales-marketing alignment, coaching vs. superhero sales leaders) that practitioners have likely encountered.

“Your deal thesis sits on the shoulders of those frontline reps in those portcos. You better make sure that they are executing right if you're going to deliver on that organic growth.”

“Do you have a sales process? Does it have to be perfect? No. But does it have fundamentals, exit criteria? Absolutely. Right. Is it in your CRM?”

While the building metaphor and foundation concept add some texture, the core advice - ICP definition, CRM discipline, sales-marketing alignment, coaching leadership - is well-worn in B2B circles. The 'data analytics sprint' and pipeline triage approaches are practical but not particularly novel. The episode lacks counterintuitive claims or fresh frameworks; it reinforces conventional wisdom about GTM fundamentals rather than challenging assumptions.

“if you've ever seen a building going up, you know that it starts with a foundation, right?”

“I don't want to see a sales leader that's a super rep. I want to see a sales leader that's a super coach, right?”

George is a managing partner at a go-to-market advisory firm with documented PE experience and has clearly worked on multiple portfolio company transformations. His operating partner-style engagement in both diligence and post-close phases demonstrates real operating experience, and the specific examples (pharmaceutical company analytics, pipeline triage initiatives) suggest meaningful scale and impact. However, he is primarily an advisor/consultant rather than a founder or executive who built and scaled a company himself, which limits the caliber slightly.

“Managing partner at Cortado Group. We are a full service go to market advisory group servicing the mid to low Mid Market. 95% of our work is within PE companies.”

“One of my PE clients that didn't use this for either of those, but use this a lot for, you know, year two, year three stuff.”

George provides some concrete examples (pharmaceutical rep model and doctor prescription tracking, the '$40 million go get' three-week sprint, Salesforce recency report for pipeline verification) that ground the discussion. However, most are light on actual metrics, dollar amounts, or named companies. The pharmaceutical example lacks specific data (how much was actually recovered?), and many recommendations remain somewhat abstract (e.g., 'map the entire buying decision team,' 'understand the compelling event') without showing the actual output or impact.

“We call it the $40 million go get right. It's an initiative, it's a three week sprint. It's data analytical intents.”

“think of a rep, um, calling on a provider who's writing prescriptions. Well they have like zero visibility into or they weren't tracking on a dashboard.”

The hosts (Scott and Nick) ask reasonably sharp follow-up questions and push on timing, sequencing, and the gap between theory and practice (e.g., 'when are you most impactful?', 'how do you play the short-term vs. long-term tension?'). However, the questions often feel like softballs that invite long monologues rather than productive pushback or disagreement. There's minimal challenge to George's claims, and the dynamic tilts toward a friendly advisory conversation rather than rigorous interrogation. The hosts don't press on failure rates, trade-offs, or alternative viewpoints.

“So I'd love to know when you guys are most impactful because I'm assuming you run some type of go to market assessment.”

“How do you play that?”